News
PLX
2.170
-3.13%
-0.070
Weekly Report: what happened at PLX last week (0303-0307)?
Weekly Report · 3d ago
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
PR Newswire · 3d ago
Weekly Report: what happened at PLX last week (0224-0228)?
Weekly Report · 03/03 11:28
Weekly Report: what happened at PLX last week (0217-0221)?
Weekly Report · 02/24 11:28
Weekly Report: what happened at PLX last week (0210-0214)?
Weekly Report · 02/17 11:25
Weekly Report: what happened at PLX last week (0203-0207)?
Weekly Report · 02/10 11:19
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
PR Newswire · 02/04 11:50
Protalix BioTherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/03 12:01
Protalix BioTherapeutics Price Target Raised to $15.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 02/03 12:01
HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $15
Benzinga · 02/03 11:51
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Protalix (PLX)
TipRanks · 02/03 11:31
Weekly Report: what happened at PLX last week (0127-0131)?
Weekly Report · 02/03 11:24
Weekly Report: what happened at PLX last week (0120-0124)?
Weekly Report · 01/27 11:27
Weekly Report: what happened at PLX last week (0113-0117)?
Weekly Report · 01/20 11:18
Weekly Report: what happened at PLX last week (0106-0110)?
Weekly Report · 01/13 11:19
Weekly Report: what happened at PLX last week (1230-0103)?
Weekly Report · 01/06 11:27
Weekly Report: what happened at PLX last week (1223-1227)?
Weekly Report · 12/30/2024 11:21
Protalix Achieves Key Milestones and Remains Debt-Free
TipRanks · 12/23/2024 12:28
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
PR Newswire · 12/23/2024 11:50
Weekly Report: what happened at PLX last week (1216-1220)?
Weekly Report · 12/23/2024 11:28
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
More
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.